서브메뉴
검색
Identification of Novel Regulators of the G1/S Cell Cycle Transition
Identification of Novel Regulators of the G1/S Cell Cycle Transition
상세정보
- 자료유형
- 학위논문 서양
- 최종처리일시
- 20260202105614
- ISBN
- 9798265428035
- DDC
- 570
- 저자명
- Hammond, Taylar.
- 서명/저자
- Identification of Novel Regulators of the G1/S Cell Cycle Transition
- 발행사항
- [Sl] : Stanford University, 2025
- 발행사항
- Ann Arbor : ProQuest Dissertations & Theses, 2025
- 형태사항
- 142 p
- 주기사항
- Source: Dissertations Abstracts International, Volume: 87-05, Section: B.
- 주기사항
- Includes supplementary digital materials.
- 주기사항
- Advisor: Sage, Julien.
- 학위논문주기
- Thesis (Ph.D.)--Stanford University, 2025.
- 초록/해제
- 요약Cell cycle is a fundamental and highly complex process which involves integration of many signaling inputs. The G1/S transition is the final decision point for commitment to cell cycle and as such is a battleground for competing pro-division and arrest signals. Cyclin D1 and p21 represent two downstream targets which are subject to a high degree of regulation and whose balancing is key to the G1/S decision point. While core actors at the G1/S transition have been defined, much remains to be discovered in the extended signaling network. In order to identify novel regulators of this key signaling hub and transition point, the following work outlines a multimodal approach to discovery of novel candidates using publicly available data and CRISPR/Cas9 screens (Chapter 2) and in-depth follow up of FAM53C as a novel regulator of Cyclin D1/p21 balancing through multiple mechanisms. I focus on the regulatory activity of FAM53C toward the dosage sensitive kinase DYRK1A, establishing FAM53C as a strong interactor and inhibitor of DYRK1A using genetic, molecular, and biochemical approaches (Chapter 3). Finally, Chapter 4 outlines a plan for further study of FAM53C in normal murine development as well as in models of DYKR1A-associated developmental diseases.
- 일반주제명
- CRISPR
- 일반주제명
- Cell death
- 일반주제명
- Eukaryotes
- 일반주제명
- Disease
- 일반주제명
- Cancer therapies
- 일반주제명
- Mutation
- 일반주제명
- Cloning
- 일반주제명
- Cyclin-dependent kinases
- 일반주제명
- Medical research
- 일반주제명
- Genomes
- 일반주제명
- Epigenetics
- 일반주제명
- Phosphorylation
- 일반주제명
- Yeast
- 일반주제명
- Tumors
- 일반주제명
- Senescence
- 일반주제명
- Genes
- 일반주제명
- Stem cells
- 일반주제명
- Cell cycle
- 일반주제명
- Bioinformatics
- 일반주제명
- Cellular biology
- 일반주제명
- Genetics
- 일반주제명
- Medicine
- 일반주제명
- Oncology
- 일반주제명
- Pharmaceutical sciences
- 기타저자
- Stanford University.
- 기본자료저록
- Dissertations Abstracts International. 87-05B.
- 전자적 위치 및 접속
- 로그인 후 원문을 볼 수 있습니다.
MARC
008260126s2025 us c eng d■001000017360748
■00520260202105614
■006m o d
■007cr#unu||||||||
■020 ▼a9798265428035
■035 ▼a(MiAaPQ)AAI32316431
■035 ▼a(MiAaPQ)Stanfordsz717dq7531
■040 ▼aMiAaPQ▼cMiAaPQ
■0820 ▼a570
■1001 ▼aHammond, Taylar.
■24510▼aIdentification of Novel Regulators of the G1/S Cell Cycle Transition
■260 ▼a[Sl]▼bStanford University▼c2025
■260 1▼aAnn Arbor▼bProQuest Dissertations & Theses▼c2025
■300 ▼a142 p
■500 ▼aSource: Dissertations Abstracts International, Volume: 87-05, Section: B.
■500 ▼aIncludes supplementary digital materials.
■500 ▼aAdvisor: Sage, Julien.
■5021 ▼aThesis (Ph.D.)--Stanford University, 2025.
■520 ▼aCell cycle is a fundamental and highly complex process which involves integration of many signaling inputs. The G1/S transition is the final decision point for commitment to cell cycle and as such is a battleground for competing pro-division and arrest signals. Cyclin D1 and p21 represent two downstream targets which are subject to a high degree of regulation and whose balancing is key to the G1/S decision point. While core actors at the G1/S transition have been defined, much remains to be discovered in the extended signaling network. In order to identify novel regulators of this key signaling hub and transition point, the following work outlines a multimodal approach to discovery of novel candidates using publicly available data and CRISPR/Cas9 screens (Chapter 2) and in-depth follow up of FAM53C as a novel regulator of Cyclin D1/p21 balancing through multiple mechanisms. I focus on the regulatory activity of FAM53C toward the dosage sensitive kinase DYRK1A, establishing FAM53C as a strong interactor and inhibitor of DYRK1A using genetic, molecular, and biochemical approaches (Chapter 3). Finally, Chapter 4 outlines a plan for further study of FAM53C in normal murine development as well as in models of DYKR1A-associated developmental diseases.
■590 ▼aSchool code: 0212.
■650 4▼aCRISPR
■650 4▼aCell death
■650 4▼aEukaryotes
■650 4▼aDisease
■650 4▼aCancer therapies
■650 4▼aMutation
■650 4▼aCloning
■650 4▼aCyclin-dependent kinases
■650 4▼aMedical research
■650 4▼aGenomes
■650 4▼aEpigenetics
■650 4▼aPhosphorylation
■650 4▼aYeast
■650 4▼aTumors
■650 4▼aSenescence
■650 4▼aGenes
■650 4▼aStem cells
■650 4▼aCell cycle
■650 4▼aBioinformatics
■650 4▼aCellular biology
■650 4▼aGenetics
■650 4▼aMedicine
■650 4▼aOncology
■650 4▼aPharmaceutical sciences
■690 ▼a0715
■690 ▼a0379
■690 ▼a0369
■690 ▼a0564
■690 ▼a0992
■690 ▼a0572
■71020▼aStanford University.
■7730 ▼tDissertations Abstracts International▼g87-05B.
■790 ▼a0212
■791 ▼aPh.D.
■792 ▼a2025
■793 ▼aEnglish
■85640▼uhttp://www.riss.kr/pdu/ddodLink.do?id=T17360748▼nKERIS▼z이 자료의 원문은 한국교육학술정보원에서 제공합니다.


